BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10863982)

  • 1. Amifostine and 2-CdA: a novel purging strategy in CML autografting?
    Korycka A; Robak T
    Eur J Haematol; 2000 May; 64(5):347-9. PubMed ID: 10863982
    [No Abstract]   [Full Text] [Related]  

  • 2. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging.
    Douay L; Hu C; Giarratana MC; Bouchet S; Conlon J; Capizzi RL; Gorin NC
    Blood; 1995 Oct; 86(7):2849-55. PubMed ID: 7670119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemia.
    Maki G; Tam YK; Berkahn L; Klingemann HG
    Bone Marrow Transplant; 2003 Jun; 31(12):1119-25. PubMed ID: 12796791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of cladribine and gemcitabine on erythroid and granulocytic progenitors from patients with chronic myeloid leukemia.
    Schirmer M; Geisen F; Tiefenthaler M; Konwalinka G
    Leuk Res; 1999 Dec; 23(12):1121-6. PubMed ID: 10613357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts.
    Yang H; Eaves C; de Lima M; Lee MS; Champlin RE; McMannis JD; Robinson SN; Niu T; Decker WK; Xing D; Ng J; Li S; Yao X; Eaves AC; Jones R; Andersson BS; Shpall EJ
    Bone Marrow Transplant; 2006 Mar; 37(6):575-82. PubMed ID: 16435011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular approaches to purging of chronic myelogenous leukemia marrow in autologous transplantation.
    Yuan T; Zhou YQ; Herst CV; Reading C; Ellersen D; Etkin M; Khouri I; Kantarjian H; Talpaz M; Deisseroth A
    Prog Clin Biol Res; 1992; 377():227-30. PubMed ID: 1438419
    [No Abstract]   [Full Text] [Related]  

  • 7. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
    Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
    Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purging efficacy of ZnPcH₁-based photodynamic therapy on chronic myeloid leukemia bone marrow.
    Huang H; Chen Y; Chen W; Wu Y
    Int J Lab Hematol; 2011 Oct; 33(5):477-82. PubMed ID: 21457188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous stem cell transplantation in chronic myeloid leukemia.
    Olavarria E
    Semin Hematol; 2007 Oct; 44(4):252-8. PubMed ID: 17961724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of amifostine in bone marrow purging.
    Cagnoni PJ; Jones RB; Bearman SI; Ross M; Hami L; Franklin WA; Capizzi R; Schein PS; Shpall EJ
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):44-8. PubMed ID: 8783666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
    Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
    Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of amifostine used alone or in combination with 2-chlorodeoxyadenosine on normal and chronic myelogenous leukemia granulocyte-macrophage progenitor cells in vitro.
    Korycka A; Robak T
    Arch Immunol Ther Exp (Warsz); 2000; 48(4):293-9. PubMed ID: 11059647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term culture of autologous bone marrow for marrow reconstitution following high-dose chemotherapy. Purging with tumor surface antigen directed human-human monoclonal antibody.
    Alonso K; Medenica R; Morehead G
    Prog Clin Biol Res; 1994; 389():111-8. PubMed ID: 7700892
    [No Abstract]   [Full Text] [Related]  

  • 14. Autografting in chronic myelogenous leukemia: new questions.
    Carella AM; Frassoni F; Negrin RS
    Leukemia; 1995 Mar; 9(3):365-9. PubMed ID: 7885034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow purging by photodynamic treatment in children with acute leukemia: cytoprotective action of amifostine.
    Danilatou V; Lydaki E; Dimitriou H; Papazoglou T; Kalmanti M
    Leuk Res; 2000 May; 24(5):427-35. PubMed ID: 10785265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of BCR/ABL-negative progenitor cells from chronic myeloid leukemia marrow.
    Leemhuis T; Leibowitz D; Cox G; Srour EF; Tricot G; Hoffman R
    Prog Clin Biol Res; 1992; 377():231-7. PubMed ID: 1279706
    [No Abstract]   [Full Text] [Related]  

  • 17. Ribozyme mediated therapy for chronic myelogenous leukemia.
    Leopold LH; Shore SK; Newkirk T; Mangan K; Reddy EP
    Prog Clin Biol Res; 1994; 389():175-82. PubMed ID: 7700900
    [No Abstract]   [Full Text] [Related]  

  • 18. [An experimental study on bone marrow purging in vitro for patients with chronic myelogenous leukemia].
    Liu J; Jiang J; Zhang Y; Wu D; Yang G; Huang X; Wei X
    Hua Xi Yi Ke Da Xue Xue Bao; 2001 Dec; 32(4):599-601. PubMed ID: 12528561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential role of amifostine (Ethyol) in haematological malignancies.
    Gorin NC
    Eur J Cancer; 1996; 32A Suppl 4():S31-9. PubMed ID: 8976820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negative selection and protection of normal progenitor cells for autografting.
    Douay L
    Bone Marrow Transplant; 1998 Sep; 22(5):423-30. PubMed ID: 9733264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.